Ardsley, N.Y.-based Acorda markets three therapies focused on countering neurological disorders. Buying Civitas would give it worldwide rights to CVT-301, a Phase 3 treatment candidate for some Parkinson's complications, as well as rights to Civitas' proprietary pulmonary delivery technology and Chelsea, Mass.-based manufacturing facilities.
http://ift.tt/1mT7KCW
http://ift.tt/1mT7KCW
No comments:
Post a Comment